A New Promoter Allows Optogenetic Vision Restoration with Enhanced Sensitivity in Macaque Retina.

The majority of inherited retinal degenerations converge on the phenotype of photoreceptor cell death. Second- and third-order neurons are spared in these diseases, making it possible to restore retinal light responses using optogenetics. Viral expression of channelrhodopsin in the third-order neurons under ubiquitous promoters was previously shown to restore visual function, albeit at light intensities above illumination safety thresholds. Here, we report (to our knowledge, for the first time) activation of macaque retinas, up to 6 months post-injection, using channelrhodopsin-Ca2+-permeable channelrhodopsin (CatCh) at safe light intensities. High-level CatCh expression was achieved due to a new promoter based on the regulatory region of the gamma-synuclein gene (SNCG) allowing strong expression in ganglion cells across species. Our promoter, in combination with clinically proven adeno-associated virus 2 (AAV2), provides CatCh expression in peri-foveolar ganglion cells responding robustly to light under the illumination safety thresholds for the human eye. On the contrary, the threshold of activation and the proportion of unresponsive cells were much higher when a ubiquitous promoter (cytomegalovirus [CMV]) was used to express CatCh. The results of our study suggest that the inclusion of optimized promoters is key in the path to clinical translation of optogenetics.

[1]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[2]  Michael H Berry,et al.  Optogenetic Vision Restoration Using Rhodopsin for Enhanced Sensitivity , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  E. Turner,et al.  Brn3a-Expressing Retinal Ganglion Cells Project Specifically to Thalamocortical and Collicular Visual Pathways , 2005, The Journal of Neuroscience.

[4]  Olivier Marre,et al.  Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Jean Bennett,et al.  Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial , 2016, The Lancet.

[6]  Jessy D. Dorn,et al.  Interim results from the international trial of Second Sight's visual prosthesis. , 2012, Ophthalmology.

[7]  V. Choi,et al.  Production of Recombinant Adeno‐Associated Viral Vectors , 1999, Current protocols in human genetics.

[8]  Volker Busskamp,et al.  Optogenetic approaches to restoring visual function in retinitis pigmentosa , 2011, Current Opinion in Neurobiology.

[9]  Edwin M Stone,et al.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics , 2008, Proceedings of the National Academy of Sciences.

[10]  G. Veres,et al.  Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  T. Léveillard,et al.  Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. , 2015, The Journal of clinical investigation.

[12]  Annette E. Allen,et al.  Restoration of Vision with Ectopic Expression of Human Rod Opsin , 2015, Current Biology.

[13]  A. Cideciyan,et al.  Retinal optogenetic therapies: clinical criteria for candidacy , 2013, Clinical genetics.

[14]  Michael J. Castle,et al.  Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.

[15]  J. Flannery,et al.  Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates , 2014, Gene Therapy.

[16]  Dirk Trauner,et al.  LiGluR restores visual responses in rodent models of inherited blindness. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  David R Williams,et al.  Intravitreal injection of AAV2 transduces macaque inner retina. , 2011, Investigative ophthalmology & visual science.

[18]  Edward S Boyden,et al.  Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  M Tamai,et al.  Immune responses to adeno-associated virus type 2 encoding channelrhodopsin-2 in a genetically blind rat model for gene therapy , 2011, Gene Therapy.

[20]  Edward S Boyden,et al.  A gene-fusion strategy for stoichiometric and co-localized expression of light-gated membrane proteins , 2011, Nature Methods.

[21]  Deniz Dalkara,et al.  In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous , 2013, Science Translational Medicine.

[22]  Siegrid Löwel,et al.  Restoring the ON Switch in Blind Retinas: Opto-mGluR6, a Next-Generation, Cell-Tailored Optogenetic Tool , 2015, PLoS biology.

[23]  Shomi S. Bhattacharya,et al.  Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait , 2010, Nature Reviews Genetics.

[24]  Karl Deisseroth,et al.  Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa , 2010, Science.

[25]  A. Sher,et al.  Photovoltaic restoration of sight with high visual acuity , 2015, Nature Medicine.

[26]  F. Cremers,et al.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial , 2014, The Lancet.

[27]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[28]  V. Choi,et al.  Production of Recombinant Adeno‐Associated Viral Vectors for In Vitro and In Vivo Use , 2007, Current protocols in molecular biology.

[29]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[30]  R. Ali,et al.  Molecular genetics and prospects for therapy of the inherited retinal dystrophies. , 2001, Current opinion in genetics & development.

[31]  Stefan R. Pulver,et al.  Independent Optical Excitation of Distinct Neural Populations , 2014, Nature Methods.

[32]  F. Werblin,et al.  Differential Targeting of Optical Neuromodulators to Ganglion Cell Soma and Dendrites Allows Dynamic Control of Center-Surround Antagonism , 2011, Neuron.

[33]  E. Bamberg,et al.  Ultra light-sensitive and fast neuronal activation with the Ca2+-permeable channelrhodopsin CatCh , 2011, Nature Neuroscience.

[34]  Eriko Sugano,et al.  Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats. , 2010, Experimental eye research.

[35]  J. Goldberg,et al.  γ-Synuclein as a marker of retinal ganglion cells , 2008, Molecular vision.

[36]  E. Bamberg,et al.  Channelrhodopsin-2, a directly light-gated cation-selective membrane channel , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Milam,et al.  Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa. , 1999, Investigative ophthalmology & visual science.

[38]  Olivier Marre,et al.  Red‐shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina , 2016, EMBO molecular medicine.

[39]  W. Feuer,et al.  Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results. , 2016, Ophthalmology.

[40]  Kathleen A. Marshall,et al.  AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness , 2012, Science Translational Medicine.

[41]  Douglas S Kim,et al.  Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration , 2008, Nature Neuroscience.

[42]  T. Aleman,et al.  Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina. , 2017, Human gene therapy.

[43]  Eriko Sugano,et al.  Restoration of the Majority of the Visual Spectrum by Using Modified Volvox Channelrhodopsin-1 , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  D. Kleinfeld,et al.  ReaChR: A red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation , 2013, Nature Neuroscience.

[45]  David A. Leopold,et al.  Brains, Genes, and Primates , 2015, Neuron.

[46]  Jessica A. Cardin,et al.  Noninvasive optical inhibition with a red-shifted microbial rhodopsin , 2014, Nature Neuroscience.

[47]  Zhuo-Hua Pan,et al.  Evaluation of AAV-mediated expression of Chop2-GFP in the marmoset retina. , 2010, Investigative ophthalmology & visual science.

[48]  David Williams,et al.  Imaging Light Responses of Foveal Ganglion Cells in the Living Macaque Eye , 2014, The Journal of Neuroscience.

[49]  Riccardo Storchi,et al.  Melanopsin Contributions to the Representation of Images in the Early Visual System , 2017, Current Biology.

[50]  S. Seregard,et al.  Photochemical damage of the retina. , 2006, Survey of ophthalmology.

[51]  A. Baiker,et al.  Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. , 2012, Human gene therapy methods.

[52]  Tushar H. Ganjawala,et al.  ChR2 Mutants at L132 and T159 with Improved Operational Light Sensitivity for Vision Restoration , 2014, PloS one.

[53]  John G. Flannery,et al.  Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells , 2014, Proceedings of the National Academy of Sciences.

[54]  A. Dizhoor,et al.  Ectopic Expression of a Microbial-Type Rhodopsin Restores Visual Responses in Mice with Photoreceptor Degeneration , 2006, Neuron.

[55]  R. Nussenblatt,et al.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.